First Patient Dosed in Phase 3 KHENERFIN Study of Sonlicromanol for m.3243A>G Primary Mitochondrial Disease Khondrion has announced a major […]
We are delighted to announce that three additional mitochondrial organisations have joined IMP, further strengthening our global network and amplifying
European Commission approves KYGEVVI® for TK2d IMP warmly welcomes the decision by the European Commission to approve KYGEVVI® (doxecitine and doxribtimine) as
Announcing IMP’s New Scientific and Medical Advisory Committee IMP is delighted to introduce our new Scientific and Medical Advisory Committee, a
New MELAS Consensus: A Critical Resource for Doctors and Patients Worldwide In November 2025, leading international experts gathered in Pisa,
MitMED – Building a European Centre of Excellence in Mitochondrial Medicine Mitochondria are central regulators of cellular life, integrating metabolism,
Growing Recognition of the Patient Voice in Research A meaningful shift is taking place in the rare disease research landscape:
Inside the Mito Town Hall: Insights That Matter The Mito Town Hall meetings have become an important annual touchpoint for
The Mitochondrial Disease Conference 2026, hosted by Mitocon on 23–24 January in Pisa, brought together clinicians, researchers, patients, and industry partners for
Setback for LHON Treatment in the US: IMP Supports Urgent Patient Need International Mito Patients (IMP), the global federation representing patient